Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.
Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.
Copyright © Louis Velazquez. All Rights Reserved.